Φορτώνει......
Population Pharmacokinetics of Cariprazine and its Major Metabolites
BACKGROUND AND OBJECTIVES: Cariprazine, a dopamine D(3)-preferring D(3)/D(2) receptor partial agonist, is approved for the treatment of adults with schizophrenia (1.5–6 mg/day) and manic/mixed (3–6 mg/day) episodes associated with bipolar I disorder. This population pharmacokinetic analysis describe...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur J Drug Metab Pharmacokinet |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer International Publishing
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811992/ https://ncbi.nlm.nih.gov/pubmed/33141308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13318-020-00650-4 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|